Richard Heyman

Richard Heyman currently serves as Chairman of the Board and Co-founder of Metacrine Inc., a biotech company developing innovative drugs for patients with metabolic disease. Previously, he was the co-founder and CEO of Aragon and Seragon Pharmaceuticals; two San Diego biotech companies focused on discovering and developing next generation therapeutics for hormone dependent cancers. Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014. Following his post-doctoral training at the Salk Institute, Dr. Heyman joined and held various roles at Ligand Pharmaceuticals, including Vice President of Research

Dr. Heyman is also actively involved in ORIC Pharmaceuticals, an oncology based biotech company where he serves as a board member and served as interim CEO from in 2015/2016. He also serves on the boards of Gritstone Oncology and Yumanity Therapeutics and was a Board member of Receptos Inc. (recently sold to Celgene). Dr. Heyman serves as Vice Chair on the Board of Trustees of the Salk Institute for Biological Studies, Board Foundation for the AACR and both the Executive Committee and Board of Visitors at the UCSD Moores Cancer Center. Dr. Heyman received a PhD in pharmacology and a BS in chemistry. He is the author or inventor on more than 120 publications and patents.